Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 34Leuprorelin literaturebiorxiv-preprint · Case report2022

Pseudocirrhosis in Metastatic Breast Cancer in a Male Successfully Treated with Leuprorelin and Anastrozole Followed by Eribulin: A Case Report

This case report illustrates a rare instance of a male breast cancer patient surviving 8 years post-diagnosis, highlighting the need for awareness of pseudocirrhosis in this population.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the leuprorelin corpus
4
Preclinical
20
Observational · this one
1
Open-label
6
Randomised
3
Reviews

Summary and findings

A 48-year-old male with stage IV ER/PR-positive breast cancer and metastasis to bone, lung, and liver was treated with radiation, Denosumab, Leuprorelin, and Anastrozole. Eight years post-treatment initiation, he continues to survive and manage long-term side effects. This case highlights the occurrence of pseudocirrhosis in male breast cancer patients.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2022

Abstract

The authors’ words, as biorxiv-preprint supplied them

Background: There are very few studies and cases in the literature describing metastatic breast cancer in the male population, accounting for less than 1% of all cases. Of those who have been reported, the vast majority fail to survive beyond 5 years from time of diagnosis. The lack of literature in this population makes it difficult for clinicians to foresee and prepare for upcoming complications in management. One of the more serious complications in managing metastatic breast cancer is the development of pseudocirrhosis, a frequent long-term side effect of chemotherapy and/or radiation typically seen in patients with malignancy in the liver.Case PresentationWe report the case of a 48-year-old male with a completely unremarkable family, medical, and social history other than a homozygous mutation in his MTHFR gene who was diagnosed with stage IV ER/PR-positive, HER-2/neu negative, BRCA1 and BRCA2-negative breast cancer with metastasis to bone, lung, and liver who was successfully treated with a regimen consisting of radiation, Denosumab, Leuprorelin, and Anastrozole. 8 years later since initiation of treatments, he continues to survive and undergo symptomatic management of long-term side-effects of his treatments.ConclusionsTo our knowledge this is the only reported case of metastatic breast cancer with pseudocirrhosis in a male patient. It is imperative to report this unique case to help increase awareness for clinicians managing other males with breast cancer. What makes this case even more reportable is the good outcome overall as our patient remains alive and well 8 years since time of diagnosis, a relatively difficult and rare feat to achieve in end-stage breast cancer.

Elsewhere in the Leuprorelin corpus

CLeuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis.Journal of biochemical and molecular toxicology · Not reported in abstract.AnimalCLeuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis.Journal of biochemical and molecular toxicology · 2026 · Not reported in abstract.AnimalCGene Therapy for Metastatic Castration-Resistant Prostate Cancer Using the JC Polyomavirus (JCPyV) Virus-Like Particles as a Gene Delivery Vector.Cancer medicine · 2026 · No significant differences in survival were observed among the MOCK, ENZ/LEU, and PSAtk-VLP/GCV groups (log-rank test, p = 0.7351).AnimalBEffects of the GnRH agonist leuprorelin on liver volume in premenopausal women with severe polycystic liver disease.Hepatology communications · 2026 · Median liver growth rate 4.04 [-4.62 to 6.84] %/year in leuprorelin group vs. 11.0 [0.70-13.2] %/year in standard care group, p=0.15.HumanBMyomatous erythrocytosis syndrome associated with an 8-kg uterine leiomyoma: a case report of diagnostic evaluation and perioperative management.Case reports in women's health · 2026 · n=1 · Hemoglobin was 20.1 g/dL at presentation, reduced to 11.4 g/dL at one-month follow-up.HumanBImproved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.The New England journal of medicine · 2026Human